Pramlintide

DEA Class; Rx

Common Brand Names; Symlin, SymlinPen 120, SymlinPen 60

  • Antidiabetics, Amylinomimetics

Synthetic injectable amylin analog
Used primarily as an adjunct to insulin in adults with type 1 and type 2 diabetes mellitus; improves glycemic control and causes modest (0.5 to 2 kg) weight loss
Slows gastric emptying, suppresses postprandial glucagon secretion

Indicated for the treatment of type 1 diabetes mellitus in patients who use mealtime insulin and who have failed to achieve desired glucose control despite optimal insulin therapy.

For the treatment of type 2 diabetes mellitus in patients who use mealtime insulin and who have failed to achieve desired glucose control despite optimal insulin therapy.

Hypersensitivity

Gastroparesis

Hypoglycemia unawareness

Nausea

Headache

Vomiting

Anorexia

Severe hypoglycemia

Inflicted injury

1-10%

Dizziness

Fatigue

Abdominal pain

Pharyngitis

Cough

Arthralgia

Allergic reaction

Injection site reactions

Risk of severe insulin-induced hypoglycemia; pramlintide alone does not cause hypoglycemia; however, since it is indicated to be coadministered with mealtime insulin therapy, and in this setting there is an increased risk of severe hypoglycemia

Do not mix with insulin – administer the two separately

Slows gastric emptying, which may delay the absorption of concomitantly administered oral medications; administer the concomitant oral medication at least 1 hr prior or 2 hr after pramlintide

Slows gastric emptying; not recommended if taking other medications that alter gastrointestinal motility

Never share pen between patients even if needle is changed

Erythema, edema, or pruritus at site of injection reported; may be related to other factors, such as irritants in a skin cleansing agent or improper injection technique

Available data from a small number of reports in manufacturer’s safety database on use in pregnant women are not sufficient to determine a drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes

There is no data on presence in human milk, effects on breastfed infant, or on milk production

Specific maximum dosage information is not available. Individualize dosage based on careful monitoring of blood glucose and other clinical parameters in all patient populations.

Pramlintide Acetate

injectable solution

  • 0.6mg/mL

pen-injector

  • 15mcg/dose
  • 30mcg/dose
  • 45mcg/dose
  • 60mcg/dose
  • 120mcg/dose

About the Author

You may also like these

0